The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.
GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group.
The group warned that many people cannot even get hold of basic insulin, critical for people with type 1 diabetes, and many countries are struggling to access GLP-1 medications at all – as the explosion in their popularity continues since the weight-loss jab Wegovy launched in 2021.
Diabetes affects an estimated 589 million adults globally, 81% of whom live in low- and middle-income countries (LMICs) such as Pakistan, Egypt and Jordan.
“A lot of the GLP-1 drugs are just starting to enter these LMIC markets for obesity,” said Jay Iyer, the…